The latest price target for Jasper Therapeutics (NASDAQ:JSPR) was reported by TD Cowen on May 15, 2026. The analyst firm set a price target for $0.00 expecting JSPR to fall to within 12 months (a possible -100.00% downside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Jasper Therapeutics (NASDAQ:JSPR) was provided by TD Cowen, and Jasper Therapeutics downgraded their hold rating.

There is no last upgrade for Jasper Therapeutics

The last downgrade for Jasper Therapeutics Inc happened on May 15, 2026 when TD Cowen changed their price target from N/A to N/A for Jasper Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jasper Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jasper Therapeutics was filed on May 15, 2026 so you should expect the next rating to be made available sometime around May 15, 2027.

While ratings are subjective and will change, the latest Jasper Therapeutics (JSPR) rating was a downgraded with a price target of $0.00 to $0.00. The current price Jasper Therapeutics (JSPR) is trading at is $0.83, which is out of the analyst’s predicted range.